TABLE 2

Matched Case-Control Analysis of Infant Hospitalizations and Death in the First 6 Months of Life in the VSD After Maternal Vaccination, 2004–2014

1:1 Matched Analysis of Hospitalizations (n = 50 444)1:1 Matched Analysis of Respiratory Hospitalizations (n = 9288)1:1 Matched Analysis of Deaths (n = 314)
Vaccine in pregnancyInfluenzaaTdapbBothcInfluenzaTdapBothInfluenzaTdapBoth
Case patients exposed, %38.712.88.638.49.97.13263
Controls exposed, %39.313.49.038.111.47.437128
Crude OR (95% CI)0.97 (0.93–1.01)0.91 (0.85–0.97)0.94 (0.87–1.01)1.02 (0.93–1.12)0.79 (0.67–0.93)0.93 (0.78–1.13)0.81 (0.49–1.31)0.41 (0.17–0.99)0.25 (0.07–0.89)
aORd (95% CI)1.00 (0.96–1.04)0.94 (0.88–1.01)0.97 (0.90–1.05)1.08 (0.97–1.19)0.79 (0.67–0.94)0.97 (0.80–1.17)0.96 (0.54–1.69)0.44 (0.17–1.13)0.32 (0.08–1.24)
Pe.93.09.44.15.007.73.87.09.10
  • aOR, adjusted odds ratio; OR odds ratio.

  • a Influenza vaccine in pregnancy given with or without Tdap vaccine.

  • b Tdap vaccine in pregnancy given with or without influenza vaccine.

  • c Both influenza and Tdap vaccines given in the same pregnancy.

  • d Adjusting for pregnancy complications, adequacy of prenatal care, smoking during pregnancy, race, maternal age, infant DTaP receipt before event, length of birth hospitalization in days, and gestational age at delivery in weeks.

  • e P values correspond to the aOR.